Modality
Radioligand
MOA
PD-1i
Target
Tau
Pathway
JAK/STAT
MelanomaCervical Ca
Development Pipeline
Preclinical
Dec 2019
→ Nov 2031
PreclinicalCurrent
NCT08162811
1,948 pts·Cervical Ca
2019-12→2031-11·Not yet recruiting
1,948 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-275.7y awayInterim· Cervical Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Not yet…
Catalysts
Interim
2031-11-27 · 5.7y away
Cervical Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08162811 | Preclinical | Cervical Ca | Not yet recr... | 1948 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Nidarelsin | Uniqure | Phase 2/3 | RET | |
| TER-5062 | Terns | Phase 2/3 | Tau | |
| EXA-971 | Exscientia | Phase 2 | CGRP |